The ACER1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of human HeLa cells engineered to disrupt the ACER1 gene, providing a versatile loss-of-function model for studying alkaline ceramidase 1-mediated sphingolipid metabolism. This polyclonal knockout pool, generated by targeted gene disruption, enables robust and reproducible investigation of ACER1-dependent cellular processes without the need for clonal isolation, making it suitable for high-throughput functional genomics and pathway analysis.
HeLa cells, derived from a cervical adenocarcinoma, are an immortalized human epithelial line extensively employed in cancer and cell biology research. Their well-characterized signaling networks, rapid proliferation, and amenability to genetic manipulation establish an ideal host background for dissecting the roles of sphingolipid-modifying enzymes in a neoplastic context. This model leverages the inherent tumorigenic properties of HeLa to explore how ACER1 deletion influences malignant cell behavior.
ACER1 encodes an endoplasmic reticulum-localized alkaline ceramidase that catalyzes the hydrolysis of very long chain ceramides into sphingosine and free fatty acids, a pivotal reaction controlling the ceramide/sphingosine-1-phosphate (S1P) rheostat. This balance is critical for cell fate decisions: ceramide promotes apoptosis, while S1P signals through S1PR1-5 receptors to support survival, proliferation, and differentiation. ACER1 activity is modulated by upstream regulators such as TNF-alpha, UV radiation, and oxidative stress, and it operates within a signaling network involving interacting factors like ceramide synthases, sphingosine kinases (SPHK1/2), and CERT. Key pathway components, including SPT, CerS, DES, SPHK, S1P lyase, and S1PRs, collectively regulate sphingolipid flux, positioning ACER1 as a central node in the conversion of pro-apoptotic ceramide to pro-survival S1P.
In HeLa cells, disruption of ACER1 profoundly alters the ceramide/S1P equilibrium, potentially sensitizing these cancer cells to apoptosis and impairing differentiation programs. Given HeLa??s epithelial origin and relevance to carcinoma research, this knockout model is instrumental for elucidating how ACER1-dependent ceramide hydrolysis supports tumor cell viability, drug resistance, and responses to sphingolipid-targeted therapeutics. Furthermore, it aids in investigating mechanistic parallels to skin barrier disorders, such as autosomal recessive congenital ichthyosis, where ACER1 mutations lead to defective epidermal homeostasis.
This polyclonal knockout population is ideally suited for a wide array of experimental applications, including sphingolipid metabolic profiling via ceramide LC-MS/MS and S1P ELISA, apoptosis signaling studies using flow cytometry and Western blotting, and functional genomics screens. It also supports drug response profiling with cell viability assays, migration assays, and immunofluorescence-based localization studies, enabling researchers to connect ACER1 loss to phenotypic and molecular alterations. For further inquiries, please contact Ascent Research.
